Obese Patients With or Without Comorbidities (RIO-North America)

NCT ID: NCT00029861


Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities
Purpose
To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
Details
Conditions
Obesity, Weight Loss
Keywords
Weight Loss, Obesity, Weight Reduction, Overweight
Source
Sanofi
Sponsors
Sanofi
Status
Completed
Acronym
Last Updated
16 Apr 2009
URL
Official Link
Citations/Publications
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group.. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006 Feb 15;295(7):761-75. Erratum in: JAMA. 2006 Mar 15;295(11):1252.

Locations
Canada, United States